Why CPAP and tirzepatide make good bedfellows: 2024 sleep conference highlights
This content has been independently produced by AusDoc, made possible through sponsorship from Eli Lilly
Numerous research studies have focused on how sleep behaviour and more specifically, obstructive sleep apnoea (OSA) impacts cardiometabolic risk, so it was unsurprising that this was one of the underlying themes at this year’s 35th annual scientific meeting of the Australasian Sleep Association and the Australian and New Zealand Sleep Science Association.
Sleep DownUnder 2024 was held at the Gold Coast from October 16 to 19, bringing together hundreds of sleep medicine professionals from the region.
Dr Peter Cistulli, a Professor of Sleep Medicine at the University of Sydney, focused on the biological links between sleep loss or sleep disturbance and cardiometabolic outcomes.
